Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Neovascular Glaucoma Prevention in Choroidal Melanoma
NCT03172299Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jun 2017
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in neovascular glaucoma (NVG), sponsored by Centre Hospitalier Universitaire de Nice. Started Jun 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT03172299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172299.